BioInfect 2014 to Gather Life Science Professionals and Set the Global Antimicrobial Agenda
Bionow will be hosting the 2014 BioInfect Conference. A major one-day conference looking at the critical issues relating to the development of new anti-infectives and the endemic problem of resistance, will take place at the Alderley Park Conference Centre, Cheshire on the 4 November 2014. The conference will again convene scientists, policy makers and government officials from across the world to drive forward and establish the global anti-microbial agenda.
The three main sessions that will be presented at the conference are “Progress: National and International Perspectives”, “Animal Health — the issues” and “Commercial Models.” In addition, there will be company technology showcases presenting leading innovation and development in this area. These include North West based Redx Anti-Infectives and Blueberry Therapeutics, QuantuMDx who are based in Newcastle and Discuva who are based in Cambridge.
Dr Geoff Davison, CEO of Bionow, commented: “To tackle growing levels of antimicrobial resistance, we need to address this global problem in a truly coordinated way to ensure that we have a health care system that can sustainably control and treat infections. BioInfect is a wonderful opportunity to bring together professionals from the life sciences industry, government and policy making bodies and explore the areas which can truly address this problem for mankind.”
BioInfect 2014 follows on from a very successful conference last year where Professor Dame Sally Davies, Chief Medical Officer, noted that "the golden age" of effective antibiotics has come to an end as no new class of drugs has been developing since 1987. She warned of the danger of going back to a pre-antibiotic era, where a simple infection could be a death sentence - a warning echoed by other speakers from around the globe. This year the Deputy Chief Medical Officer, Professor John Watson will inform delegates of the progress which the UK is making in the fight against this deadly threat.
BioInfect 2014, is hosted by Bionow and Redx Pharma, supported by AstraZeneca and sponsored by HGF Ltd, Boyd Consultants, Shore Capital and DWF LLP.
Related News
-
News Swiss pharma industry warns US tariffs could harm global patient care
The Swiss pharmaceutical sector has raised alarms over new US tariffs on medicines, warning of disrupted supply chains, increased costs, and delayed innovation, all of which could jeopardise patient access to essential treatments worldwide.
-
News Women in Pharma: CPHI India – India’s Pharmaceutical Industry and Gender Inclusion Challenges
India’s pharmaceutical industry has emerged as a significant player in the global market, valued at USD 50 billion in FY 2023-2024, according to Frost & Sullivan’s analysis. This sector encompasses a diverse portfolio, including drugs, vacc... -
News Biogen acquires Apellis Pharmaceuticals to boost immunology and rare disease profile
Biogen Inc. has announced its acquisition of Apellis Pharmaceuticals, Inc., a move that is set to significantly enhance its growth portfolio in immunology and rare diseases. The agreement, valued at approximately US$5.6 billion, will see Biogen purchas... -
News Gilead Sciences acquires Ouro Medicines for over US$2 billion
Gilead Sciences confirms a deal to take over Ouro Medicines, adding to a portfolio of therapies for autoimmune diseases.
-
News Women in Pharma: Advancing Women's Health
Discover the latest innovations in technologies and therapeutics that are revolutionising women's health in our latest CPHI Online Women in Pharma infographic.
-
News CPHI Pharma Awards 2026: Recognising Excellence in an Evolving Industry
Submissions now open — deadline May 16
-
News Dr Reddy's to launch generic semaglutide in India
Dr Reddy’s Laboratories, one of India’s leading pharmaceutical companies, is preparing to launch a generic version of semaglutide, branded as Obeda, in March. Obeda is expected to provide a more affordable alternative to Ozempic a... -
News Frontier Biotech and GSK Forge RNA Therapy Partnership
Frontier Biotechnologies and GSK have entered a global licensing agreement to advance small interfering RNA (siRNA) therapeutics. This collaboration grants GSK exclusive rights to develop and commercialise two promising siRNA candidates, marking a mile...